BioGaia AB (publ) (BIOGY) Stock Competitors & Peer Comparison
See (BIOGY) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIOGY | $11.00 | +0.00% | 1.1B | 31.43 | $0.35 | +3.84% |
| MKGAF | $155.60 | -3.44% | 67.8B | 23.21 | $6.72 | +1.71% |
| MKKGY | $31.02 | -2.39% | 67.4B | 23.15 | $1.34 | +1.66% |
| IPSEY | $46.75 | +0.00% | 61.8B | 30.56 | $1.53 | +0.99% |
| TKPHF | $34.28 | +11.23% | 54.2B | 46.32 | $0.74 | +3.81% |
| HLNCF | $4.53 | +1.68% | 40B | 18.12 | $0.25 | +2.11% |
| SDZNY | $84.33 | +0.05% | 36.5B | 40.35 | $2.09 | +1.21% |
| TEVJF | $30.34 | +0.00% | 35.3B | 22.64 | $1.34 | N/A |
| TAIPY | $14.00 | +16.67% | 18.1B | 82.35 | $0.17 | N/A |
| ESALY | $61.51 | -2.11% | 17.6B | 20.54 | $3.00 | N/A |
Stock Comparison
BIOGY vs MKGAF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MKGAF has a market cap of 67.8B. Regarding current trading prices, BIOGY is priced at $11.00, while MKGAF trades at $155.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas MKGAF's P/E ratio is 23.21. In terms of profitability, BIOGY's ROE is +0.26%, compared to MKGAF's ROE of +0.08%. Regarding short-term risk, BIOGY is less volatile compared to MKGAF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MKGAF's competition here
BIOGY vs MKKGY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MKKGY has a market cap of 67.4B. Regarding current trading prices, BIOGY is priced at $11.00, while MKKGY trades at $31.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas MKKGY's P/E ratio is 23.15. In terms of profitability, BIOGY's ROE is +0.26%, compared to MKKGY's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to MKKGY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MKKGY's competition here
BIOGY vs IPSEY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IPSEY has a market cap of 61.8B. Regarding current trading prices, BIOGY is priced at $11.00, while IPSEY trades at $46.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas IPSEY's P/E ratio is 30.56. In terms of profitability, BIOGY's ROE is +0.26%, compared to IPSEY's ROE of +0.10%. Regarding short-term risk, BIOGY is less volatile compared to IPSEY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check IPSEY's competition here
BIOGY vs TKPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TKPHF has a market cap of 54.2B. Regarding current trading prices, BIOGY is priced at $11.00, while TKPHF trades at $34.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TKPHF's P/E ratio is 46.32. In terms of profitability, BIOGY's ROE is +0.26%, compared to TKPHF's ROE of +0.03%. Regarding short-term risk, BIOGY and TKPHF have similar daily volatility (0.00).Check TKPHF's competition here
BIOGY vs HLNCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLNCF has a market cap of 40B. Regarding current trading prices, BIOGY is priced at $11.00, while HLNCF trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HLNCF's P/E ratio is 18.12. In terms of profitability, BIOGY's ROE is +0.26%, compared to HLNCF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to HLNCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HLNCF's competition here
BIOGY vs SDZNY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SDZNY has a market cap of 36.5B. Regarding current trading prices, BIOGY is priced at $11.00, while SDZNY trades at $84.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SDZNY's P/E ratio is 40.35. In terms of profitability, BIOGY's ROE is +0.26%, compared to SDZNY's ROE of +0.10%. Regarding short-term risk, BIOGY is less volatile compared to SDZNY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SDZNY's competition here
BIOGY vs TEVJF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TEVJF has a market cap of 35.3B. Regarding current trading prices, BIOGY is priced at $11.00, while TEVJF trades at $30.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TEVJF's P/E ratio is 22.64. In terms of profitability, BIOGY's ROE is +0.26%, compared to TEVJF's ROE of +0.21%. Regarding short-term risk, BIOGY and TEVJF have similar daily volatility (0.00).Check TEVJF's competition here
BIOGY vs TAIPY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TAIPY has a market cap of 18.1B. Regarding current trading prices, BIOGY is priced at $11.00, while TAIPY trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TAIPY's P/E ratio is 82.35. In terms of profitability, BIOGY's ROE is +0.26%, compared to TAIPY's ROE of +0.02%. Regarding short-term risk, BIOGY is less volatile compared to TAIPY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TAIPY's competition here
BIOGY vs ESALY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESALY has a market cap of 17.6B. Regarding current trading prices, BIOGY is priced at $11.00, while ESALY trades at $61.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ESALY's P/E ratio is 20.54. In terms of profitability, BIOGY's ROE is +0.26%, compared to ESALY's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to ESALY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESALY's competition here
BIOGY vs BIOVF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BIOVF has a market cap of 16.6B. Regarding current trading prices, BIOGY is priced at $11.00, while BIOVF trades at $48.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas BIOVF's P/E ratio is 171.43. In terms of profitability, BIOGY's ROE is +0.26%, compared to BIOVF's ROE of +0.02%. Regarding short-term risk, BIOGY is less volatile compared to BIOVF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BIOVF's competition here
BIOGY vs SGIOY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGIOY has a market cap of 14.7B. Regarding current trading prices, BIOGY is priced at $11.00, while SGIOY trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SGIOY's P/E ratio is 11.55. In terms of profitability, BIOGY's ROE is +0.26%, compared to SGIOY's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to SGIOY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGIOY's competition here
BIOGY vs SGIOF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGIOF has a market cap of 13.6B. Regarding current trading prices, BIOGY is priced at $11.00, while SGIOF trades at $16.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SGIOF's P/E ratio is 10.67. In terms of profitability, BIOGY's ROE is +0.26%, compared to SGIOF's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to SGIOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGIOF's competition here
BIOGY vs IPSEF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IPSEF has a market cap of 9.3B. Regarding current trading prices, BIOGY is priced at $11.00, while IPSEF trades at $113.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas IPSEF's P/E ratio is 18.07. In terms of profitability, BIOGY's ROE is +0.26%, compared to IPSEF's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to IPSEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check IPSEF's competition here
BIOGY vs ESALF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESALF has a market cap of 6.7B. Regarding current trading prices, BIOGY is priced at $11.00, while ESALF trades at $23.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ESALF's P/E ratio is 28.09. In terms of profitability, BIOGY's ROE is +0.26%, compared to ESALF's ROE of +0.04%. Regarding short-term risk, BIOGY is less volatile compared to ESALF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESALF's competition here
BIOGY vs ESAIY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ESAIY has a market cap of 6.6B. Regarding current trading prices, BIOGY is priced at $11.00, while ESAIY trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ESAIY's P/E ratio is 27.90. In terms of profitability, BIOGY's ROE is +0.26%, compared to ESAIY's ROE of +0.04%. Regarding short-term risk, BIOGY is less volatile compared to ESAIY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ESAIY's competition here
BIOGY vs BCHMF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BCHMF has a market cap of 6.5B. Regarding current trading prices, BIOGY is priced at $11.00, while BCHMF trades at $87.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas BCHMF's P/E ratio is 35.08. In terms of profitability, BIOGY's ROE is +0.26%, compared to BCHMF's ROE of +0.11%. Regarding short-term risk, BIOGY is less volatile compared to BCHMF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BCHMF's competition here
BIOGY vs GZPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GZPHF has a market cap of 6.2B. Regarding current trading prices, BIOGY is priced at $11.00, while GZPHF trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GZPHF's P/E ratio is 9.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to GZPHF's ROE of +0.08%. Regarding short-term risk, BIOGY and GZPHF have similar daily volatility (0.00).Check GZPHF's competition here
BIOGY vs LVZPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LVZPF has a market cap of 6.1B. Regarding current trading prices, BIOGY is priced at $11.00, while LVZPF trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LVZPF's P/E ratio is 15.35. In terms of profitability, BIOGY's ROE is +0.26%, compared to LVZPF's ROE of +0.14%. Regarding short-term risk, BIOGY is less volatile compared to LVZPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LVZPF's competition here
BIOGY vs HLUBF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLUBF has a market cap of 5.8B. Regarding current trading prices, BIOGY is priced at $11.00, while HLUBF trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HLUBF's P/E ratio is 9.48. In terms of profitability, BIOGY's ROE is +0.26%, compared to HLUBF's ROE of +0.15%. Regarding short-term risk, BIOGY is less volatile compared to HLUBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HLUBF's competition here
BIOGY vs HLBBF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLBBF has a market cap of 5.8B. Regarding current trading prices, BIOGY is priced at $11.00, while HLBBF trades at $7.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HLBBF's P/E ratio is 14.29. In terms of profitability, BIOGY's ROE is +0.26%, compared to HLBBF's ROE of +0.15%. Regarding short-term risk, BIOGY and HLBBF have similar daily volatility (0.00).Check HLBBF's competition here
BIOGY vs SFOSF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SFOSF has a market cap of 5.3B. Regarding current trading prices, BIOGY is priced at $11.00, while SFOSF trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SFOSF's P/E ratio is 10.63. In terms of profitability, BIOGY's ROE is +0.26%, compared to SFOSF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to SFOSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SFOSF's competition here
BIOGY vs LABFF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LABFF has a market cap of 4.6B. Regarding current trading prices, BIOGY is priced at $11.00, while LABFF trades at $90.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LABFF's P/E ratio is 28.95. In terms of profitability, BIOGY's ROE is +0.26%, compared to LABFF's ROE of +0.21%. Regarding short-term risk, BIOGY and LABFF have similar daily volatility (0.00).Check LABFF's competition here
BIOGY vs SGFEF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SGFEF has a market cap of 4.4B. Regarding current trading prices, BIOGY is priced at $11.00, while SGFEF trades at $100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SGFEF's P/E ratio is 20.75. In terms of profitability, BIOGY's ROE is +0.26%, compared to SGFEF's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to SGFEF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SGFEF's competition here
BIOGY vs HKMPY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HKMPY has a market cap of 4.3B. Regarding current trading prices, BIOGY is priced at $11.00, while HKMPY trades at $40.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HKMPY's P/E ratio is 11.19. In terms of profitability, BIOGY's ROE is +0.26%, compared to HKMPY's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to HKMPY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HKMPY's competition here
BIOGY vs DNPUF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DNPUF has a market cap of 4.2B. Regarding current trading prices, BIOGY is priced at $11.00, while DNPUF trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas DNPUF's P/E ratio is 5.58. In terms of profitability, BIOGY's ROE is +0.26%, compared to DNPUF's ROE of +0.42%. Regarding short-term risk, BIOGY is less volatile compared to DNPUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DNPUF's competition here
BIOGY vs HKMPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HKMPF has a market cap of 4.1B. Regarding current trading prices, BIOGY is priced at $11.00, while HKMPF trades at $19.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HKMPF's P/E ratio is 10.66. In terms of profitability, BIOGY's ROE is +0.26%, compared to HKMPF's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to HKMPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HKMPF's competition here
BIOGY vs SMDPY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SMDPY has a market cap of 4.1B. Regarding current trading prices, BIOGY is priced at $11.00, while SMDPY trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SMDPY's P/E ratio is 5.39. In terms of profitability, BIOGY's ROE is +0.26%, compared to SMDPY's ROE of +0.42%. Regarding short-term risk, BIOGY is less volatile compared to SMDPY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SMDPY's competition here
BIOGY vs APNHY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, APNHY has a market cap of 3.9B. Regarding current trading prices, BIOGY is priced at $11.00, while APNHY trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas APNHY's P/E ratio is -34.84. In terms of profitability, BIOGY's ROE is +0.26%, compared to APNHY's ROE of -0.02%. Regarding short-term risk, BIOGY and APNHY have similar daily volatility (0.00).Check APNHY's competition here
BIOGY vs APNHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, APNHF has a market cap of 3.9B. Regarding current trading prices, BIOGY is priced at $11.00, while APNHF trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas APNHF's P/E ratio is -34.80. In terms of profitability, BIOGY's ROE is +0.26%, compared to APNHF's ROE of -0.02%. Regarding short-term risk, BIOGY is less volatile compared to APNHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check APNHF's competition here
BIOGY vs LBTSF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LBTSF has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while LBTSF trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LBTSF's P/E ratio is 59.04. In terms of profitability, BIOGY's ROE is +0.26%, compared to LBTSF's ROE of +0.04%. Regarding short-term risk, BIOGY and LBTSF have similar daily volatility (0.00).Check LBTSF's competition here
BIOGY vs CAMRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CAMRF has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while CAMRF trades at $54.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CAMRF's P/E ratio is 45.41. In terms of profitability, BIOGY's ROE is +0.26%, compared to CAMRF's ROE of +0.16%. Regarding short-term risk, BIOGY and CAMRF have similar daily volatility (0.00).Check CAMRF's competition here
BIOGY vs CHSYF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CHSYF has a market cap of 3.3B. Regarding current trading prices, BIOGY is priced at $11.00, while CHSYF trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CHSYF's P/E ratio is 13.50. In terms of profitability, BIOGY's ROE is +0.26%, compared to CHSYF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to CHSYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CHSYF's competition here
BIOGY vs INVVY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, INVVY has a market cap of 3B. Regarding current trading prices, BIOGY is priced at $11.00, while INVVY trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas INVVY's P/E ratio is -62.42. In terms of profitability, BIOGY's ROE is +0.26%, compared to INVVY's ROE of -0.42%. Regarding short-term risk, BIOGY and INVVY have similar daily volatility (0.00).Check INVVY's competition here
BIOGY vs HYPMY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HYPMY has a market cap of 2.9B. Regarding current trading prices, BIOGY is priced at $11.00, while HYPMY trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HYPMY's P/E ratio is 8.43. In terms of profitability, BIOGY's ROE is +0.26%, compared to HYPMY's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to HYPMY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HYPMY's competition here
BIOGY vs IZQVF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, IZQVF has a market cap of 2.9B. Regarding current trading prices, BIOGY is priced at $11.00, while IZQVF trades at $20.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas IZQVF's P/E ratio is -56.68. In terms of profitability, BIOGY's ROE is +0.26%, compared to IZQVF's ROE of -0.99%. Regarding short-term risk, BIOGY and IZQVF have similar daily volatility (0.00).Check IZQVF's competition here
BIOGY vs CURLF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CURLF has a market cap of 2.8B. Regarding current trading prices, BIOGY is priced at $11.00, while CURLF trades at $10.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CURLF's P/E ratio is -24.83. In terms of profitability, BIOGY's ROE is +0.26%, compared to CURLF's ROE of -0.13%. Regarding short-term risk, BIOGY is less volatile compared to CURLF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CURLF's competition here
BIOGY vs ULIHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ULIHF has a market cap of 2.4B. Regarding current trading prices, BIOGY is priced at $11.00, while ULIHF trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ULIHF's P/E ratio is 7.75. In terms of profitability, BIOGY's ROE is +0.26%, compared to ULIHF's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to ULIHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ULIHF's competition here
BIOGY vs TCNNF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TCNNF has a market cap of 2.2B. Regarding current trading prices, BIOGY is priced at $11.00, while TCNNF trades at $11.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TCNNF's P/E ratio is -28.87. In terms of profitability, BIOGY's ROE is +0.26%, compared to TCNNF's ROE of -0.07%. Regarding short-term risk, BIOGY is less volatile compared to TCNNF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TCNNF's competition here
BIOGY vs NPNKF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NPNKF has a market cap of 2.1B. Regarding current trading prices, BIOGY is priced at $11.00, while NPNKF trades at $31.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas NPNKF's P/E ratio is 11.42. In terms of profitability, BIOGY's ROE is +0.26%, compared to NPNKF's ROE of +0.11%. Regarding short-term risk, BIOGY is less volatile compared to NPNKF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NPNKF's competition here
BIOGY vs HTSUF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HTSUF has a market cap of 2B. Regarding current trading prices, BIOGY is priced at $11.00, while HTSUF trades at $29.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HTSUF's P/E ratio is 16.76. In terms of profitability, BIOGY's ROE is +0.26%, compared to HTSUF's ROE of +0.07%. Regarding short-term risk, BIOGY and HTSUF have similar daily volatility (0.00).Check HTSUF's competition here
BIOGY vs DMPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DMPHF has a market cap of 2B. Regarding current trading prices, BIOGY is priced at $11.00, while DMPHF trades at $39.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas DMPHF's P/E ratio is 17.90. In terms of profitability, BIOGY's ROE is +0.26%, compared to DMPHF's ROE of +0.21%. Regarding short-term risk, BIOGY is less volatile compared to DMPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DMPHF's competition here
BIOGY vs ARSUF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ARSUF has a market cap of 1.9B. Regarding current trading prices, BIOGY is priced at $11.00, while ARSUF trades at $26.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ARSUF's P/E ratio is 18.55. In terms of profitability, BIOGY's ROE is +0.26%, compared to ARSUF's ROE of +0.17%. Regarding short-term risk, BIOGY is less volatile compared to ARSUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ARSUF's competition here
BIOGY vs DUTV Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, DUTV has a market cap of 1.9B. Regarding current trading prices, BIOGY is priced at $11.00, while DUTV trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas DUTV's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.26%, compared to DUTV's ROE of -0.09%. Regarding short-term risk, BIOGY is less volatile compared to DUTV. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check DUTV's competition here
BIOGY vs HMDCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HMDCF has a market cap of 1.9B. Regarding current trading prices, BIOGY is priced at $11.00, while HMDCF trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HMDCF's P/E ratio is 4.08. In terms of profitability, BIOGY's ROE is +0.26%, compared to HMDCF's ROE of +0.41%. Regarding short-term risk, BIOGY is less volatile compared to HMDCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HMDCF's competition here
BIOGY vs GTBIF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GTBIF has a market cap of 1.8B. Regarding current trading prices, BIOGY is priced at $11.00, while GTBIF trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GTBIF's P/E ratio is 15.88. In terms of profitability, BIOGY's ROE is +0.26%, compared to GTBIF's ROE of +0.07%. Regarding short-term risk, BIOGY is less volatile compared to GTBIF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GTBIF's competition here
BIOGY vs TSMRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TSMRF has a market cap of 1.7B. Regarding current trading prices, BIOGY is priced at $11.00, while TSMRF trades at $23.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TSMRF's P/E ratio is 10.04. In terms of profitability, BIOGY's ROE is +0.26%, compared to TSMRF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to TSMRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TSMRF's competition here
BIOGY vs SHPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHPHF has a market cap of 1.7B. Regarding current trading prices, BIOGY is priced at $11.00, while SHPHF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SHPHF's P/E ratio is -6.22. In terms of profitability, BIOGY's ROE is +0.26%, compared to SHPHF's ROE of +0.03%. Regarding short-term risk, BIOGY and SHPHF have similar daily volatility (0.00).Check SHPHF's competition here
BIOGY vs NPPNY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NPPNY has a market cap of 1.6B. Regarding current trading prices, BIOGY is priced at $11.00, while NPPNY trades at $6.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas NPPNY's P/E ratio is 8.84. In terms of profitability, BIOGY's ROE is +0.26%, compared to NPPNY's ROE of +0.11%. Regarding short-term risk, BIOGY is less volatile compared to NPPNY. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NPPNY's competition here
BIOGY vs MITPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MITPF has a market cap of 1.6B. Regarding current trading prices, BIOGY is priced at $11.00, while MITPF trades at $23.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas MITPF's P/E ratio is -10.81. In terms of profitability, BIOGY's ROE is +0.26%, compared to MITPF's ROE of +4.99%. Regarding short-term risk, BIOGY is less volatile compared to MITPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MITPF's competition here
BIOGY vs KARBF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KARBF has a market cap of 1.5B. Regarding current trading prices, BIOGY is priced at $11.00, while KARBF trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas KARBF's P/E ratio is 262.50. In terms of profitability, BIOGY's ROE is +0.26%, compared to KARBF's ROE of N/A. Regarding short-term risk, BIOGY and KARBF have similar daily volatility (0.00).Check KARBF's competition here
BIOGY vs CMOPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CMOPF has a market cap of 1.5B. Regarding current trading prices, BIOGY is priced at $11.00, while CMOPF trades at $87.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CMOPF's P/E ratio is -336.15. In terms of profitability, BIOGY's ROE is +0.26%, compared to CMOPF's ROE of -0.01%. Regarding short-term risk, BIOGY is less volatile compared to CMOPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CMOPF's competition here
BIOGY vs SWGHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SWGHF has a market cap of 1.3B. Regarding current trading prices, BIOGY is priced at $11.00, while SWGHF trades at $11.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SWGHF's P/E ratio is 15.57. In terms of profitability, BIOGY's ROE is +0.26%, compared to SWGHF's ROE of +0.06%. Regarding short-term risk, BIOGY and SWGHF have similar daily volatility (0.00).Check SWGHF's competition here
BIOGY vs EVOTF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, EVOTF has a market cap of 1.2B. Regarding current trading prices, BIOGY is priced at $11.00, while EVOTF trades at $6.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas EVOTF's P/E ratio is -5.31. In terms of profitability, BIOGY's ROE is +0.26%, compared to EVOTF's ROE of -0.25%. Regarding short-term risk, BIOGY is less volatile compared to EVOTF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check EVOTF's competition here
BIOGY vs LJUIF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LJUIF has a market cap of 1.2B. Regarding current trading prices, BIOGY is priced at $11.00, while LJUIF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LJUIF's P/E ratio is 13.42. In terms of profitability, BIOGY's ROE is +0.26%, compared to LJUIF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to LJUIF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LJUIF's competition here
BIOGY vs CHIZF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CHIZF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while CHIZF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CHIZF's P/E ratio is -21.89. In terms of profitability, BIOGY's ROE is +0.26%, compared to CHIZF's ROE of -0.01%. Regarding short-term risk, BIOGY is less volatile compared to CHIZF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CHIZF's competition here
BIOGY vs CASBF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CASBF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while CASBF trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CASBF's P/E ratio is 155.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to CASBF's ROE of -0.00%. Regarding short-term risk, BIOGY is less volatile compared to CASBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CASBF's competition here
BIOGY vs KSPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KSPHF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while KSPHF trades at $25.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas KSPHF's P/E ratio is 12.45. In terms of profitability, BIOGY's ROE is +0.26%, compared to KSPHF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to KSPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KSPHF's competition here
BIOGY vs GNMLF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GNMLF has a market cap of 1.1B. Regarding current trading prices, BIOGY is priced at $11.00, while GNMLF trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GNMLF's P/E ratio is 12.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to GNMLF's ROE of +0.11%. Regarding short-term risk, BIOGY is less volatile compared to GNMLF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GNMLF's competition here
BIOGY vs GLASF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GLASF has a market cap of 1B. Regarding current trading prices, BIOGY is priced at $11.00, while GLASF trades at $13.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GLASF's P/E ratio is -20.38. In terms of profitability, BIOGY's ROE is +0.26%, compared to GLASF's ROE of -0.26%. Regarding short-term risk, BIOGY is less volatile compared to GLASF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GLASF's competition here
BIOGY vs KKPCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KKPCF has a market cap of 984.6M. Regarding current trading prices, BIOGY is priced at $11.00, while KKPCF trades at $26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas KKPCF's P/E ratio is 288.89. In terms of profitability, BIOGY's ROE is +0.26%, compared to KKPCF's ROE of +0.01%. Regarding short-term risk, BIOGY is less volatile compared to KKPCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KKPCF's competition here
BIOGY vs TWAPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TWAPF has a market cap of 828.5M. Regarding current trading prices, BIOGY is priced at $11.00, while TWAPF trades at $16.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TWAPF's P/E ratio is 6.28. In terms of profitability, BIOGY's ROE is +0.26%, compared to TWAPF's ROE of +0.03%. Regarding short-term risk, BIOGY is less volatile compared to TWAPF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TWAPF's competition here
BIOGY vs CSWYF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CSWYF has a market cap of 758.4M. Regarding current trading prices, BIOGY is priced at $11.00, while CSWYF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CSWYF's P/E ratio is 4.78. In terms of profitability, BIOGY's ROE is +0.26%, compared to CSWYF's ROE of +0.12%. Regarding short-term risk, BIOGY is less volatile compared to CSWYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CSWYF's competition here
BIOGY vs TRXPF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TRXPF has a market cap of 690.7M. Regarding current trading prices, BIOGY is priced at $11.00, while TRXPF trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TRXPF's P/E ratio is 25.86. In terms of profitability, BIOGY's ROE is +0.26%, compared to TRXPF's ROE of +0.03%. Regarding short-term risk, BIOGY and TRXPF have similar daily volatility (0.00).Check TRXPF's competition here
BIOGY vs SHEZF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHEZF has a market cap of 689M. Regarding current trading prices, BIOGY is priced at $11.00, while SHEZF trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SHEZF's P/E ratio is -23.48. In terms of profitability, BIOGY's ROE is +0.26%, compared to SHEZF's ROE of +0.03%. Regarding short-term risk, BIOGY is less volatile compared to SHEZF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check SHEZF's competition here
BIOGY vs KHTRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, KHTRF has a market cap of 663.7M. Regarding current trading prices, BIOGY is priced at $11.00, while KHTRF trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas KHTRF's P/E ratio is 169.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to KHTRF's ROE of +0.01%. Regarding short-term risk, BIOGY is less volatile compared to KHTRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check KHTRF's competition here
BIOGY vs AGYTF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AGYTF has a market cap of 655.5M. Regarding current trading prices, BIOGY is priced at $11.00, while AGYTF trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas AGYTF's P/E ratio is -13.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to AGYTF's ROE of +2.84%. Regarding short-term risk, BIOGY and AGYTF have similar daily volatility (0.00).Check AGYTF's competition here
BIOGY vs YIHCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, YIHCF has a market cap of 643.1M. Regarding current trading prices, BIOGY is priced at $11.00, while YIHCF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas YIHCF's P/E ratio is -5.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to YIHCF's ROE of +0.06%. Regarding short-term risk, BIOGY and YIHCF have similar daily volatility (0.00).Check YIHCF's competition here
BIOGY vs AIHLF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AIHLF has a market cap of 624.3M. Regarding current trading prices, BIOGY is priced at $11.00, while AIHLF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas AIHLF's P/E ratio is 10.94. In terms of profitability, BIOGY's ROE is +0.26%, compared to AIHLF's ROE of +0.15%. Regarding short-term risk, BIOGY and AIHLF have similar daily volatility (0.00).Check AIHLF's competition here
BIOGY vs TRSSF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, TRSSF has a market cap of 601.9M. Regarding current trading prices, BIOGY is priced at $11.00, while TRSSF trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas TRSSF's P/E ratio is -1.32. In terms of profitability, BIOGY's ROE is +0.26%, compared to TRSSF's ROE of -0.76%. Regarding short-term risk, BIOGY is less volatile compared to TRSSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check TRSSF's competition here
BIOGY vs BOIRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BOIRF has a market cap of 553.9M. Regarding current trading prices, BIOGY is priced at $11.00, while BOIRF trades at $31.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas BOIRF's P/E ratio is 14.63. In terms of profitability, BIOGY's ROE is +0.26%, compared to BOIRF's ROE of +0.05%. Regarding short-term risk, BIOGY is less volatile compared to BOIRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BOIRF's competition here
BIOGY vs PKBFF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PKBFF has a market cap of 544.7M. Regarding current trading prices, BIOGY is priced at $11.00, while PKBFF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas PKBFF's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.26%, compared to PKBFF's ROE of +7.96%. Regarding short-term risk, BIOGY and PKBFF have similar daily volatility (0.00).Check PKBFF's competition here
BIOGY vs CCHWF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CCHWF has a market cap of 521.3M. Regarding current trading prices, BIOGY is priced at $11.00, while CCHWF trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CCHWF's P/E ratio is -1.12. In terms of profitability, BIOGY's ROE is +0.26%, compared to CCHWF's ROE of +0.42%. Regarding short-term risk, BIOGY is less volatile compared to CCHWF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CCHWF's competition here
BIOGY vs SWDCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SWDCF has a market cap of 500.3M. Regarding current trading prices, BIOGY is priced at $11.00, while SWDCF trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SWDCF's P/E ratio is 104.33. In terms of profitability, BIOGY's ROE is +0.26%, compared to SWDCF's ROE of +0.01%. Regarding short-term risk, BIOGY and SWDCF have similar daily volatility (0.00).Check SWDCF's competition here
BIOGY vs VRNOF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, VRNOF has a market cap of 470.4M. Regarding current trading prices, BIOGY is priced at $11.00, while VRNOF trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas VRNOF's P/E ratio is -1.31. In terms of profitability, BIOGY's ROE is +0.26%, compared to VRNOF's ROE of -0.31%. Regarding short-term risk, BIOGY is less volatile compared to VRNOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check VRNOF's competition here
BIOGY vs PEXXF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PEXXF has a market cap of 463.1M. Regarding current trading prices, BIOGY is priced at $11.00, while PEXXF trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas PEXXF's P/E ratio is 9.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to PEXXF's ROE of N/A. Regarding short-term risk, BIOGY and PEXXF have similar daily volatility (0.00).Check PEXXF's competition here
BIOGY vs ELTP Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ELTP has a market cap of 362.1M. Regarding current trading prices, BIOGY is priced at $11.00, while ELTP trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ELTP's P/E ratio is 8.40. In terms of profitability, BIOGY's ROE is +0.26%, compared to ELTP's ROE of +0.71%. Regarding short-term risk, BIOGY is less volatile compared to ELTP. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ELTP's competition here
BIOGY vs HUMDF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HUMDF has a market cap of 338.9M. Regarding current trading prices, BIOGY is priced at $11.00, while HUMDF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HUMDF's P/E ratio is 2.13. In terms of profitability, BIOGY's ROE is +0.26%, compared to HUMDF's ROE of +1.07%. Regarding short-term risk, BIOGY is less volatile compared to HUMDF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check HUMDF's competition here
BIOGY vs CPHRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CPHRF has a market cap of 297.1M. Regarding current trading prices, BIOGY is priced at $11.00, while CPHRF trades at $11.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CPHRF's P/E ratio is 9.87. In terms of profitability, BIOGY's ROE is +0.26%, compared to CPHRF's ROE of +0.26%. Regarding short-term risk, BIOGY is less volatile compared to CPHRF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CPHRF's competition here
BIOGY vs CRLBF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CRLBF has a market cap of 295.6M. Regarding current trading prices, BIOGY is priced at $11.00, while CRLBF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CRLBF's P/E ratio is -2.20. In terms of profitability, BIOGY's ROE is +0.26%, compared to CRLBF's ROE of -0.35%. Regarding short-term risk, BIOGY is less volatile compared to CRLBF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CRLBF's competition here
BIOGY vs GUERF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, BIOGY is priced at $11.00, while GUERF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GUERF's P/E ratio is 8.19. In terms of profitability, BIOGY's ROE is +0.26%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, BIOGY and GUERF have similar daily volatility (0.00).Check GUERF's competition here
BIOGY vs BHCCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BHCCF has a market cap of 225.1M. Regarding current trading prices, BIOGY is priced at $11.00, while BHCCF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas BHCCF's P/E ratio is -4.57. In terms of profitability, BIOGY's ROE is +0.26%, compared to BHCCF's ROE of +0.29%. Regarding short-term risk, BIOGY is less volatile compared to BHCCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BHCCF's competition here
BIOGY vs NIKA Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NIKA has a market cap of 211.8M. Regarding current trading prices, BIOGY is priced at $11.00, while NIKA trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas NIKA's P/E ratio is N/A. In terms of profitability, BIOGY's ROE is +0.26%, compared to NIKA's ROE of +0.27%. Regarding short-term risk, BIOGY is less volatile compared to NIKA. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NIKA's competition here
BIOGY vs PLNHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, PLNHF has a market cap of 202M. Regarding current trading prices, BIOGY is priced at $11.00, while PLNHF trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas PLNHF's P/E ratio is -3.50. In terms of profitability, BIOGY's ROE is +0.26%, compared to PLNHF's ROE of +838111.55%. Regarding short-term risk, BIOGY is less volatile compared to PLNHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check PLNHF's competition here
BIOGY vs CBWTF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CBWTF has a market cap of 160.3M. Regarding current trading prices, BIOGY is priced at $11.00, while CBWTF trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CBWTF's P/E ratio is 11.20. In terms of profitability, BIOGY's ROE is +0.26%, compared to CBWTF's ROE of +0.16%. Regarding short-term risk, BIOGY is less volatile compared to CBWTF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check CBWTF's competition here
BIOGY vs COPHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, COPHF has a market cap of 131.7M. Regarding current trading prices, BIOGY is priced at $11.00, while COPHF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas COPHF's P/E ratio is -0.02. In terms of profitability, BIOGY's ROE is +0.26%, compared to COPHF's ROE of -5.75%. Regarding short-term risk, BIOGY is less volatile compared to COPHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check COPHF's competition here
BIOGY vs NWPN Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, NWPN has a market cap of 123.7M. Regarding current trading prices, BIOGY is priced at $11.00, while NWPN trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas NWPN's P/E ratio is -0.04. In terms of profitability, BIOGY's ROE is +0.26%, compared to NWPN's ROE of +0.13%. Regarding short-term risk, BIOGY is less volatile compared to NWPN. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check NWPN's competition here
BIOGY vs LOVFF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LOVFF has a market cap of 121.5M. Regarding current trading prices, BIOGY is priced at $11.00, while LOVFF trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LOVFF's P/E ratio is 15.38. In terms of profitability, BIOGY's ROE is +0.26%, compared to LOVFF's ROE of +0.09%. Regarding short-term risk, BIOGY is less volatile compared to LOVFF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LOVFF's competition here
BIOGY vs BIOYF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, BIOYF has a market cap of 114.4M. Regarding current trading prices, BIOGY is priced at $11.00, while BIOYF trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas BIOYF's P/E ratio is 17.86. In terms of profitability, BIOGY's ROE is +0.26%, compared to BIOYF's ROE of +0.22%. Regarding short-term risk, BIOGY is less volatile compared to BIOYF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check BIOYF's competition here
BIOGY vs GRUSF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, GRUSF has a market cap of 112.5M. Regarding current trading prices, BIOGY is priced at $11.00, while GRUSF trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas GRUSF's P/E ratio is 45.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to GRUSF's ROE of +0.01%. Regarding short-term risk, BIOGY is less volatile compared to GRUSF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check GRUSF's competition here
BIOGY vs LPCUF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, LPCUF has a market cap of 112.1M. Regarding current trading prices, BIOGY is priced at $11.00, while LPCUF trades at $0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas LPCUF's P/E ratio is 9.51. In terms of profitability, BIOGY's ROE is +0.26%, compared to LPCUF's ROE of +0.06%. Regarding short-term risk, BIOGY is less volatile compared to LPCUF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check LPCUF's competition here
BIOGY vs AAWH Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, AAWH has a market cap of 109.3M. Regarding current trading prices, BIOGY is priced at $11.00, while AAWH trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas AAWH's P/E ratio is -0.84. In terms of profitability, BIOGY's ROE is +0.26%, compared to AAWH's ROE of +5.41%. Regarding short-term risk, BIOGY is less volatile compared to AAWH. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check AAWH's competition here
BIOGY vs CNVCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, CNVCF has a market cap of 109.2M. Regarding current trading prices, BIOGY is priced at $11.00, while CNVCF trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas CNVCF's P/E ratio is -5.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to CNVCF's ROE of +1.21%. Regarding short-term risk, BIOGY and CNVCF have similar daily volatility (0.00).Check CNVCF's competition here
BIOGY vs HLTRF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, HLTRF has a market cap of 98.5M. Regarding current trading prices, BIOGY is priced at $11.00, while HLTRF trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas HLTRF's P/E ratio is -9.84. In terms of profitability, BIOGY's ROE is +0.26%, compared to HLTRF's ROE of -0.17%. Regarding short-term risk, BIOGY and HLTRF have similar daily volatility (0.00).Check HLTRF's competition here
BIOGY vs JUSHF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, JUSHF has a market cap of 97.3M. Regarding current trading prices, BIOGY is priced at $11.00, while JUSHF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas JUSHF's P/E ratio is -1.35. In terms of profitability, BIOGY's ROE is +0.26%, compared to JUSHF's ROE of +0.66%. Regarding short-term risk, BIOGY is less volatile compared to JUSHF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check JUSHF's competition here
BIOGY vs MEDXF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, MEDXF has a market cap of 94.3M. Regarding current trading prices, BIOGY is priced at $11.00, while MEDXF trades at $2.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas MEDXF's P/E ratio is -146.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to MEDXF's ROE of -0.01%. Regarding short-term risk, BIOGY is less volatile compared to MEDXF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check MEDXF's competition here
BIOGY vs SHIEF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, SHIEF has a market cap of 85.6M. Regarding current trading prices, BIOGY is priced at $11.00, while SHIEF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas SHIEF's P/E ratio is -4.00. In terms of profitability, BIOGY's ROE is +0.26%, compared to SHIEF's ROE of +1.18%. Regarding short-term risk, BIOGY and SHIEF have similar daily volatility (0.00).Check SHIEF's competition here
BIOGY vs ABSCF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ABSCF has a market cap of 78.1M. Regarding current trading prices, BIOGY is priced at $11.00, while ABSCF trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ABSCF's P/E ratio is -37.33. In terms of profitability, BIOGY's ROE is +0.26%, compared to ABSCF's ROE of +0.07%. Regarding short-term risk, BIOGY is less volatile compared to ABSCF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ABSCF's competition here
BIOGY vs ORXOF Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, ORXOF has a market cap of 73.8M. Regarding current trading prices, BIOGY is priced at $11.00, while ORXOF trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas ORXOF's P/E ratio is -1.64. In terms of profitability, BIOGY's ROE is +0.26%, compared to ORXOF's ROE of -2.28%. Regarding short-term risk, BIOGY is less volatile compared to ORXOF. This indicates potentially lower risk in terms of short-term price fluctuations for BIOGY.Check ORXOF's competition here
BIOGY vs EOFBY Comparison June 2026
BIOGY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIOGY stands at 1.1B. In comparison, EOFBY has a market cap of 73.7M. Regarding current trading prices, BIOGY is priced at $11.00, while EOFBY trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIOGY currently has a P/E ratio of 31.43, whereas EOFBY's P/E ratio is -7.67. In terms of profitability, BIOGY's ROE is +0.26%, compared to EOFBY's ROE of -0.77%. Regarding short-term risk, BIOGY and EOFBY have similar daily volatility (0.00).Check EOFBY's competition here